Clinical Trial Update: Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Niraparib-TSR-042 (Dostarlimab) to physician's choice chemotherapy in recurrent ovarian/fallopian tube/primary peritoneal cancer patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Niraparib-TSR-042 (dostarlimab)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Ovarian Cancer | Phase 3 | Status: UNKNOWN